Overview

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.
Phase:
Phase 4
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
LCZ 696
Valsartan